Master the 2024 updates to pharmacotherapy for Type 2 diabetes.
The 2024 Update to the Clinical Practice Guidelines introduces critical shifts in the management of Type 2 diabetes, prioritizing cardiorenal protection alongside glycemic control. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the latest evidence-based recommendations for selecting antihyperglycemic agents based on comorbidities like heart failure, chronic kidney disease (CKD), and cardiovascular risk.
Key Topics Covered:
Initial Therapy: Confirming metformin as the first-line agent for most patients and knowing when to initiate insulin immediately.
Cardiorenal Protection: Identifying the specific indications for GLP-1 Receptor Agonists (GLP1-RA) and SGLT2 Inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or CKD.
Glycemic Targets: Recalling when to add second-line agents (e.g., when A1C is >1.5% above target) and the benefits of combination therapy.
Safety & Side Effects: Reviewing the risk of euglycemic DKA with SGLT2 inhibitors and contraindications for GLP1-RAs.
Weight Management: Understanding the role of specific agents (e.g., Semaglutide, Tirzepatide) in weight loss and metabolic health.